Evodiamine Lowers Blood Lipids by Up-Regulating the PPARγ/ABCG1 Pathway in High-Fat-Diet-Fed Mice.
Xingming HouClemens MalainerAtanas G AtanasovElke H HeißVerena M DirschLimei WangKe-Wei WangPublished in: Journal of natural products (2021)
The natural alkaloid evodiamine enhances cholesterol efflux from cultured THP-1-derived macrophages, but whether it has any impact on blood lipids in vivo remains unknown. In this study, the effect of evodiamine on hyperlipidemia induced by a high-fat diet (HFD) was investigated in mice. Intragastric administrations of evodiamine (10 and 20 mg/kg) for 8 weeks resulted in a significant improvement of metabolic lipid profiles by reducing the plasma levels of triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C). Evodiamine also significantly decreased hepatic lipid accumulation and hepatic total bile acids (TBA). Mechanistically, evodiamine increased ATP-binding cassette transporter G1 (ABCG1) mRNA and protein expression and up-regulated peroxisome proliferator-activated receptor gamma (PPARγ) expression in the liver. Taken together, the natural product evodiamine lowers blood lipids in HFD-fed mice likely through promoting the PPARγ-ABCG1 signaling pathway.
Keyphrases
- high fat diet
- insulin resistance
- high fat diet induced
- adipose tissue
- fatty acid
- signaling pathway
- metabolic syndrome
- skeletal muscle
- type diabetes
- binding protein
- low density lipoprotein
- transcription factor
- epithelial mesenchymal transition
- cell proliferation
- endothelial cells
- long non coding rna
- pi k akt
- high resolution
- mass spectrometry
- gestational age
- preterm birth